{
  "slug": "access-consortium",
  "name": "Access Consortium",
  "description": "The Access Consortium is an international collaboration among regulatory authorities from the UK, Australia, Canada, Singapore, and Switzerland. It aims to streamline the market authorization process for new active substances (NASWSI) and biosimilars (BSWSI) by facilitating work-sharing assessment procedures, reducing duplication, and promoting regulatory cooperation.",
  "url": "https://optimly.ai/brand/access-consortium",
  "websiteUrl": "https://accessconsortium.info/",
  "logoUrl": "https://logo.clearbit.com/accessconsortium.info",
  "baiScore": 33,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": "Incumbent",
  "archetype_status": "active",
  "category": "Regulatory Affairs",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-08-09T00:02:33.158Z",
  "verifiedVitals": {
    "website": "https://accessconsortium.info",
    "headquarters": "International (comprising multiple national regulatory authorities)",
    "pricing_model": "National fees apply to applicants based on the specific regulatory authority and type of application. The consortium itself does not charge additional fees for its coordination services.",
    "core_products": "Work-sharing assessment procedures for New Active Substances (NASWSI) and Biosimilars (BSWSI) marketing authorization applications.",
    "key_differentiator": "Provides a collaborative, work-sharing framework for concurrent review of new active substance and biosimilar applications across multiple independent national regulatory authorities, reducing redundant assessment efforts and potentially accelerating multi-market access while preserving national decision-making.",
    "target_markets": "Pharmaceutical companies seeking regulatory approval for new active substances and biosimilars in the United Kingdom, Australia, Canada, Singapore, and Switzerland.",
    "subcategory": "Pharmaceutical Regulatory Review"
  },
  "intentTags": {
    "problemIntents": [
      "Individual National Regulatory Submissions: Instead of participating in the Access Consortium's work-sharing, a pharmaceutical company could opt to submit full, independent applications to each nation",
      "Regulatory Affairs Consultancy Services: Companies can engage specialized regulatory affairs consultancies to manage and navigate the complexities of multi-jurisdictional drug approval processes, whet",
      "Limited Market Authorization Scope: A company might choose to limit the market authorization of its new active substance or biosimilar to fewer countries, or only a single primary market, to avoid the"
    ],
    "solutionIntents": [
      "Access Consortium New Active Substance Work-Sharing",
      "Access Consortium biosimilar application process",
      "NASWSI operational procedures",
      "How to apply for Access Consortium",
      "Access Consortium participating countries"
    ],
    "evaluationIntents": []
  },
  "timestamp": 1786462743753
}